CEO Tony Cataldo to Present at the LD Micro Invitational Conference

LOS ANGELES, CA / ACCESSWIRE / June 3, 2016 / Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. (OTCQB: OXIS and Euronext Paris: OXI.PA), announced that CEO Tony Cataldo will be presenting at the LD Micro Invitational Conference on June 7, 2016, at 3:00pm PST. The conference will be held on June 7-9 at the Luxe Hotel on Sunset Boulevard in Los Angeles, California.

The LD Micro Invitational is one of the most influential venues in the micro-cap world today. Oxis will join 200 other companies for three days of presentations and private meetings.

CEO Tony Cataldo said, “We have spent a lot of time developing our assets and gathering pristine data. I believe the LD Micro Invitational is the perfect venue to present all of the Company’s recent accomplishments and ongoing developments.”

About Oxis International, Inc.

Oxis International, Inc., through its subsidiary Oxis Biotech, Inc., is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS’ lead drug candidate, OXS-1550 (DT2219ARL), is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of the drug’s cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS’ lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. For more information about Oxis Biotech and it product pipeline, please visit http://www.oxis.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Oxis International, Inc.

ReleaseID: 440722